A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins

International Journal of Cancer

Volumn 103, Issue 2, 2003, Pages 277-282

  Heisler, Iring ^a   Keller, Jutta ^a   Tauber, Rudolf ^a   Sutherland, Mark ^a   Fuchs, Hendrik ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cleavable adapter; Epidermal growth factor; Immunotoxins; Saporin

Indexed keywords

ADENINE; BACTERIAL TOXIN; COMPLEMENTARY DNA; CYTOSOLIC CLEAVABLE PEPTIDE; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOTOXIN; PEPTIDE; PLASMID DNA; PSEUDOMONAS EXOTOXIN; RECOMBINANT IMMUNOTOXIN; SAPORIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL STRAIN MCF 7; CYTOTOXICITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADENINE; CELL DIVISION; DNA PRIMERS; EPIDERMAL GROWTH FACTOR; GLYCOSIDE HYDROLASES; HALF-LIFE; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOTOXINS; N-GLYCOSYL HYDROLASES; PLANT PROTEINS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0037427781     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10809     Document Type: Article

References (26)

1. Bolognesi A, Polito L, Tazzari PL, Lemoli RM, Lubelli C, Fogli M, Boon L, de Boer M, Stirpe F. In vitro anti-tumour activity of antiCD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol 2000;110:351-61.
2. Munoz R, Arias Y, Ferreras JM, Jimenez P, Rojo MA, Girbes T. Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating protein nigrin b. Cancer Lett 2001;167:163-9.
3. Brinkmann U. Recombinant antibody fragments and immunotoxin fusions for cancer therapy. In Vivo 2000;14:21-7.
4. Chandler LA, Sosnowski BA, McDonald JR, Price JE, Aukerman SL, Baird A, Pierce GF, Houston LL. Targeting tumor cells via EGF receptors: Selective toxicity of an HBEGF-toxin fusion protein. Int J Cancer 1998;78:106-11.
5. Leland P, Taguchi J, Husain SR, Kreitman RJ, Pastan I, Puri RK. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol Med 2000;6:165-78.
6. Piascik P. FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc (Wash) 1999;39:571-2.
7. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11 (Suppl 2): S81-91.
8. Kreitman RJ. Chimeric fusion proteins - Pseudomonas exotoxinbased. Curr Opin Investig Drugs 2001;2:1282-93.
9. Vitetta ES. Immunotoxins and vascular leak syndrome. Cancer J Sci Am 2000;6 (Suppl 3):S218-24.
10. Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang Q, Kreitman RJ, Lee B, Pastan I. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 2001;61:5070-7.
11. Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 1994;269:18167-76.
12. Chaudhary VK, Jinno Y, FitzGerald D, Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA 1990;87:308-12.
13. Bolognesi A, Tazzari PL, Olivieri F, Polito L, Falini B, Stirpe F. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. Int J Cancer 1996;68:349-55.
14. Keppler-Hatkemeyer A, Kreitman RJ, Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer 2000;87:86-94.
15. Keller J, Heisler I, Tauber R, Fuchs H. Development of a novel molecular adapter for the optimization of immunotoxins. J Control Release 2001;74:259-61.
16. Oess S, Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther 2000;7:750-8.
17. Heisler I, Keller J, Tauber R, Sutherland M, Fuchs H. A colorimetric assay for the quantitation of free adenine applied to determine the enzymatic activity of ribosome-inactivating proteins. Anal Biochem 2002;302:114-22.
18. Nygren P, Fridborg H, Csoka K, Sundstrom C, de la Torre M, Kristensen J, Bergh J, Hagberg H, Glimelius B, Rastad J, Tholander B, Larsson R. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 1994;56:715-20.
19. Zhou J, Bai Y, Weiner H. Proteolysis prevents in vivo chimeric fusion protein import into yeast mitochondria. Cytosolic cleavage and subcellular distribution. J Biol Chem 1995;270:16689-93.
20. Cavallaro U, Nykjaer A, Nielsen M, Soria MR. Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. Eur J Biochem 1995;232:165-71.
21. Siegall CB, Haggerty HG, Warner GL, Chace D, Mixan B, Linsley PS, Davidson T. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. J Immunol 1997;159:5168-73.
22. Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res 2001;61:1227-32.
23. Ballard FJ. Regulation of protein breakdown by epidermal growth factor in A431 cells. Exp Cell Res 1985;157:172-80.
24. Pandiella A, Magni M, Lovisolo D, Meldolesi J. The effect of epidermal growth factor on membrane potential. Rapid hyperpolarization followed by persistent fluctuations. J Biol Chem 1989;264:12914-21.
25. Rojas M, Donahue JP, Tan Z, Lin YZ. Genetic engineering of proteins with cell membrane permeability. Nat Biotechnol 1998;16:370-5.
26. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: The penetration system for intracellular delivery. Trends Cell Biol 1998;8:84-7.